Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3759-3762

  Lu, Yipin ^a,b   Nikolovska Coleska, Zaneta ^a,b   Fang, Xueliang ^a,b   Gao, Wei ^a,b   Shangary, Sanjeev ^a,b   Qiu, Su ^a,b   Qin, Dongguang ^a,b   Wang, Shaomeng ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [ANILINO (PHENYL)METHYL] 2 METHYL 8 QUINOLINOL; NSC 66811; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; QUINOLINOL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL; COMPLEX FORMATION; DATA BASE; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; HCT116 CELLS; HUMANS; HYDROXYQUINOLINES; MODELS, MOLECULAR; MOLECULAR MIMICRY; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2; STEREOISOMERISM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745645832     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060023+     Document Type: Article

References (22)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
2. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network. Nature 2000, 408, 6810, 307-310.
3. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2, 594-604.
4. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 2003, 3, 102-109.
5. Vassilev, L. T.; p53 Activation by small molecules: Application in oncology, J. Med. Chem. 2005, 48, 4491-4499.
6. Hainaut, P.; Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000 77, 81-137.
7. Momand, J.; Wu, H. H.; Dasgupta, G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000, 242, 15-29.
8. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
9. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Tomita, Y.; Parrish, D. A.; Deschamps, J. R.; Wang, S. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 2005, 127, 10130-10131.
10. Grasberger, B. L.; Lu, T.; Schubert, C.; Parks, D. J.; Carver, T. E.; Koblish, H. K.; Cummings, M. D.; LaFrance, L. V.; Milkiewicz, K. L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S.; Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella, E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A. C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005, 48, 909-912.
11. Yin, H.; Lee, G.-I.; Park, H.-S.; Payne, G. A.; Rodriguez, J. M.; Sebti, S. M.; Hamilton, A. D. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew. Chem., Int. Ed. 2005, 44, 2704-2707.
12. Stoll, R.; Renner, C.; Hansen, S.; Palme, S.; Klein, C.; Belling, A.; Zeslawski, W.; Kamionka, M.; Rehm, T.; Muhlhahn, P.; Schumacher, R.; Hesse, F.; Kaluza, B.; Voelter, W.; Engh, R. A.; Holak, T. A. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001, 40, 336-344.
13. Galatin, P. S.; Abraham, D. J. A nonpeptide sulfonamide inhibits the p53-Mdm2 interaction and activates p53-dependent transcription in Mdm2-overexpressing cells. J. Med. Chem. 2004, 47, 4163-4165.
14. Recent review: Deng, J.; Dayam, R.; Neamati, N. Patented small-molecule inhibitors of p53-MDM2 interaction. Expert Opin, Ther. Pat. 2006, 16, 165-188.
15. Wang, R.; Lai, L.; Wang, S. Further development of consensus scoring functions for structure-based drug design. J. Comput.-Aided Mol. Des. 2002, 16, 11-26.
16. Wang, R.; Lu, Y.; Fang, X.; Wang, S. An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J. Chem. Inf. Comput. Sci. 2004, 44, 2114-2125.
17. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
18. Milne, G. W. A.; Nicklaus, M. C.; Driscoll, J. S.; Wang, S.; Zaharevitz, D. National Cancer Institute Drug Information System 3D Database. J. Chem. Inf. Comput. Sci. 1994, 34, 1219-1224.
19. Voigt, J. H.; Bienfait, B.; Wang, S.; Nicklaus, M. C. Comparison of the NCI open database with seven large chemical structural databases. J. Chem. Inf. Comput. Sci. 2001, 41, 702-712.
20. Fang, X.; Wang, S. A Web-based 3D-database pharmacophore searching tool for drug discovery. J. Chem. Inf. Comput. Sci. 2002, 42, 192-198.
21. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
22. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.